Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MB-CART19.1 |
Synonyms | |
Therapy Description |
MB-CART19.1 consists of CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and containing 4-1-BBz, which potentially inhibits tumor growth (Blood (2021) 138 (Supplement 1): 3836; NCI Drug Dictionary). |